Alphamab Oncology disclosed that it bought back 230,000 ordinary shares on 2 November 2026 via on-exchange transactions, paying an aggregate HK$1.39 million. The repurchase was executed within a price band of HK$5.985 to HK$6.12 per share, translating to a volume-weighted average cost of HK$6.06 per share.

Following the transaction, the company’s outstanding share count (excluding treasury shares) decreased to 965.92 million, while treasury shares rose to 8.46 million. The total issued share capital remained unchanged at 974.38 million shares. The latest buyback represents 0.0238% of the company’s issued shares (excluding treasury shares) as of the previous balance date.

The purchases were made under the share-repurchase mandate approved on 12 June 2026, which authorises Alphamab Oncology to acquire up to 96.85 million shares. Cumulative repurchases under this mandate have reached 2.59 million shares, equivalent to 0.27% of the company’s issued shares at the mandate date, utilising roughly 2.67% of the authorised limit.

All 230,000 shares acquired on 2 November have been retained as treasury shares; none have been cancelled. In line with Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 2 December 2026.